FDA lifts partial clinical hold on Innate's cancer drug after patient death linked to disease progression
The FDA has lifted a partial clinical hold on Innate Pharma’s IND for its potential cancer drug lacutamab after it first imposed the hold in October.
The agency’s hold followed a patient death in Innate’s Phase II TELLOMAK trial, which was first thought to have stemmed from hemophagocytic lymphohistiocytosis, a rare hematologic disorder where certain white blood cells build up in and damage organs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
